Literature DB >> 15193414

Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships.

Renate Spohn1, Ute Buwitt-Beckmann, Roland Brock, Günther Jung, Artur J Ulmer, Karl-Heinz Wiesmüller.   

Abstract

Bacterial lipoproteins and their synthetic analogues (sLP) are strong immune modulators of the early host responses after infection. Synthetic lipopeptides are strong adjuvants for the adaptive immune system. Lipoproteins and lipopeptides induce signalling in immune cells through Toll-like receptor-TLR2/TLR1 heterodimers. By screening a combinatorial lipohexapeptide amide collection in an in vitro IL-8 induction assay, we systematically evaluated the potential of 19 proteinogenic amino acids in the peptide moiety of Pam3Cys-lipopeptides to interact with TLR2. New Pam3Cys-lipopeptides with high activity were obtained. Different fatty acids were introduced to investigate the influence of the acyl moiety. Lipopeptides with modifications in the core structure of the unusual amino acid S-glycerylcysteine were synthesized and tested for IL-8 induction via TLR2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193414     DOI: 10.1016/j.vaccine.2003.11.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

Review 2.  Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.

Authors:  E G Rhee; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

3.  The Staphylococcus aureus lipoprotein SitC colocalizes with Toll-like receptor 2 (TLR2) in murine keratinocytes and elicits intracellular TLR2 accumulation.

Authors:  P Müller; M Müller-Anstett; J Wagener; Q Gao; S Kaesler; M Schaller; T Biedermann; F Götz
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

4.  Immune Response Modulation of Conjugated Agonists with Changing Linker Length.

Authors:  Keun Ah Ryu; Katarzyna Slowinska; Troy Moore; Aaron Esser-Kahn
Journal:  ACS Chem Biol       Date:  2016-10-25       Impact factor: 5.100

Review 5.  Toll or toll-free adjuvant path toward the optimal vaccine development.

Authors:  Ken J Ishii; Shizuo Akira
Journal:  J Clin Immunol       Date:  2007-03-17       Impact factor: 8.317

6.  Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.

Authors:  Pamela Thompson; Vani Lakshminarayanan; Nitin T Supekar; Judy M Bradley; Peter A Cohen; Margreet A Wolfert; Sandra J Gendler; Geert-Jan Boons
Journal:  Chem Commun (Camb)       Date:  2015-05-29       Impact factor: 6.222

7.  Robust immune responses elicited by a fully synthetic three-component vaccine.

Authors:  Sampat Ingale; Margreet A Wolfert; Jidnyasa Gaekwad; Therese Buskas; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2007-09-02       Impact factor: 15.040

8.  Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.

Authors:  Sampat Ingale; Margreet A Wolfert; Therese Buskas; Geert-Jan Boons
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

9.  Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.

Authors:  Olivier Renaudet; Gargi Dasgupta; Ilham Bettahi; Alda Shi; Anthony B Nesburn; Pascal Dumy; Lbachir BenMohamed
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

10.  Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells.

Authors:  Matthew R Kimbrell; Hemamali Warshakoon; Jens R Cromer; Subbalakshmi Malladi; Jennifer D Hood; Rajalakshmi Balakrishna; Tandace A Scholdberg; Sunil A David
Journal:  Immunol Lett       Date:  2008-04-18       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.